InsidersTradesSigma
SI-BONE, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the SI-BONE, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, SI-BONE, Inc. has recorded 252 public disclosures. Market capitalisation: €758.8m. The latest transaction was reported on 9 June 2026 (Attribution). Among the most active insiders: DUNN JEFFREY W. All data is free.
252
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€10m
166 ops.
Sell Volume
55Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,110 of 25,619 companies
35.0
score / 100
Value29
Quality41
FCF yld-1.2%
Earn yld-2.4%
EV/EBITDA·
ROE-9.6%
Gross mgn80%
Net mgn-9.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 9 June 2026
Declarations252 total
10,957 shares0Common stockSEC:0001216628-26-000003:0
10,957 shares0Common StockSEC:0001035986-26-000004:0
3,575 shares@ US$15.24620.0063% mcap1.6% of flowCommon StockSEC:0001035986-26-000004:1
10,957 shares0Common StockSEC:0001492082-26-000002:0
12,064 shares@ US$4.320.0071% mcap11.7% of flowCommon StockSEC:0001492082-26-000001:0
3,780 shares@ US$14.47060.0075% mcap12.3% of flowCommon StockSEC:0001492082-26-000001:1
3,500 shares@ US$14.13940.0068% mcap11.1% of flowCommon StockSEC:0001492082-26-000001:2
1,948 shares@ US$19.625224.8% of flowCommon StockSEC:0001853089-26-000001
1,948 shares@ US$19.62520.0052% mcap24.8% of flowCommon StockSEC:0001853089-26-000001:0
867 shares@ US$18.432410.3% of flowCommon StockSEC:0001562180-25-005490
867 shares@ US$18.43240.0022% mcap10.3% of flowCommon StockSEC:0001562180-25-005490:0
40 shares@ US$19.80350.1% of flowCommon StockSEC:0001562180-25-004056:0
100 shares@ US$20.0250.2% of flowCommon StockSEC:0001562180-25-004055:0
250 shares@ US$20.0080.3% of flowCommon StockSEC:0001562180-25-004057:0
1,477 shares@ US$19.70318.2% of flowCommon StockSEC:0001562180-25-004054:0
4,937 shares@ US$19.024910.9% of flowCommon StockSEC:0001562180-25-003848:0
38,504 shares@ US$17.176636.1% of flowCommon StockSEC:0001562180-25-003727:0
4,937 shares@ US$17.00219.5% of flowCommon StockSEC:0001562180-25-003726:0
336 shares@ US$13.7750.1% of flowCommon StockSEC:0001562180-25-003529:0
21,367 shares@ US$4.6827.8% of flowCommon StockSEC:0001562180-25-003528:0
34 shares@ US$13.860.1% of flowCommon StockSEC:0001562180-25-003007:0
1,557 shares@ US$14.0852.6% of flowCommon StockSEC:0001562180-25-003005:0
1,754 shares@ US$14.17072.5% of flowCommon StockSEC:0001562180-25-003006:0
940 shares@ US$17.36821.7% of flowCommon StockSEC:0001562180-25-001486:0
1,044 shares@ US$16.56081.0% of flowCommon StockSEC:0001562180-25-001488:0
25 of 252 declarations
About SI-BONE, Inc.
SI-BONE, Inc. is a U.S.-based medical device company listed on the Nasdaq in the United States. The company focuses on sacropelvic and musculoskeletal disorders, with a particular emphasis on sacroiliac (SI) joint dysfunction and related fusion procedures. Founded in 2008 in Delaware and headquartered in Santa Clara, California, SI-BONE built its franchise around a clinically differentiated implant platform and a strong evidence-based positioning in a niche segment of orthopedic surgery. Its early leadership came from the iFuse system, a minimally invasive, triangular implant designed for SI joint fusion, which helped establish the company as an early mover in this category. ([investor.si-bone.com](https://investor.si-bone.com/static-files/56c626d7-ed89-4866-8e5e-a4fa04e47f7a?utm_source=openai)) From an operating perspective, SI-BONE sells procedural solutions to surgeons, hospitals, and ambulatory care providers, rather than operating as a broad orthopedic conglomerate. Its product portfolio now extends beyond the original iFuse platform and includes iFuse-3D, iFuse TORQ, iFuse Bedrock Granite, and iFuse INTRA, among others. This line expansion is important strategically: management has been repositioning the company from a single-product story toward a broader “compromised bone” solutions platform that can address additional clinical use cases in the pelvis, trauma, and spine-adjacent segments. ([investor.si-bone.com](https://investor.si-bone.com/static-files/56c626d7-ed89-4866-8e5e-a4fa04e47f7a?utm_source=openai)) Competitively, SI-BONE’s moat is based on first-mover advantage, a long clinical track record, surgeon education, and the company’s accumulated regulatory and reimbursement experience. In a specialty market where physician adoption and payer coverage are critical, SI-BONE has emphasized published clinical data, FDA clearances, and continued product iteration as sources of differentiation. The business remains primarily U.S.-driven, but it has also been expanding internationally, including launches in Europe and broader commercial activity outside the U.S. ([investor.si-bone.com](https://investor.si-bone.com/news-releases/news-release-details/si-bone-inc-announces-publication-5-year-follow-data-ifuse?utm_source=openai)) Recent developments have been supportive of the growth narrative. In 2025, SI-BONE reported strong revenue growth and highlighted improving profitability metrics, alongside favorable reimbursement progress. The company also continued to broaden its portfolio with new product launches and line extensions, while announcing a distribution agreement with Smith+Nephew to improve market access for certain solutions. For equity investors, SI-BONE is best viewed as an innovation-led, specialty medtech company with a focused franchise, a growing international footprint, and multiple execution catalysts tied to product adoption, reimbursement, and commercial expansion. ([investor.si-bone.com](https://investor.si-bone.com/news-releases/news-release-details/si-bone-inc-reports-record-financial-results-fourth-quarter-2025/?utm_source=openai))
